Citi raised the firm’s price target on Argenx (ARGX) to $1,124 from $1,041 and keeps a Buy rating on the shares. The firm left a meeting with management with more confidence in Argenx’s commercial potential. Citi’s U.S. neurologist survey points to continued expansion opportunities in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy for the company.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx removed from Best Ideas List at Wedbush
- Argenx: Strong Market Position and Growth Potential Justify Buy Rating
- Argenx price target raised to $925 from $830 at JPMorgan
- Promising Outlook for arGEN X: Robust Sales Projections and Strategic Expansion Drive Positive Risk-Reward Balance
- Denali says chief medical officer Carole Ho to depart to join Eli Lilly